| 2023/03/22 17:31:37 | |
|---|---|
| Price | |
| 76.20 CHF | |
| Difference | -0.90% (-0.69) |
General attributes
| ISIN | CH0012005267 |
| Symbol | NOVN |
| Exchange | SIX Swiss Exchange |
| Currency | CHF |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 169,072 EUR |
| Benchmark | SWISS MARKET INDEX |
Market data
| Bid (Bid size) | 76.19 CHF (19,944) |
| Ask (Ask size) | 76.20 CHF (147,069) |
| Open | 76.95 CHF |
| High | 77.08 CHF |
| Low | 76.20 CHF |
| Close (prev. day) | 76.89 CHF |
| VWAP | 76.399669 CHF |
| Volume (pcs) | 5,397,074 |
| Trading volume | 412,334,666.63 |
| Number of trades | 12,766 |
| Last size | 1,000 |
Futures and Options
| Related Futures | 30 |
| Related Options | - |
PDF Downloads
| Company report: NOVARTIS AG |  |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Recent research
| Date | Headline | Download | |
| 2023/03/16 |
|
Global Equity Ratings |
|
| 2023/03/10 |
|
Global Equity Ratings |
|
| 2023/02/27 |
|
Global Equity Ratings |
|
| 2023/02/07 |
|
Global Equity Ratings |
|
| 2023/01/30 |
|
Global Equity Ratings |
|
| 2023/03/22 17:31:37 | |
|---|---|
| Price | |
| 76.20 CHF | |
| Difference | -0.90% (-0.69) |
General attributes
| ISIN | CH0012005267 |
| Symbol | NOVN |
| Exchange | SIX Swiss Exchange |
| Currency | CHF |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 169,072 EUR |
| Benchmark | SWISS MARKET INDEX |
Market data
| Bid (Bid size) | 76.19 CHF (19,944) |
| Ask (Ask size) | 76.20 CHF (147,069) |
| Open | 76.95 CHF |
| High | 77.08 CHF |
| Low | 76.20 CHF |
| Close (prev. day) | 76.89 CHF |
| VWAP | 76.399669 CHF |
| Volume (pcs) | 5,397,074 |
| Trading volume | 412,334,666.63 |
| Number of trades | 12,766 |
| Last size | 1,000 |
Performance and Risk
| 6m | 1Y | 3Y | |
| Perf (%) | +1.53% | -4.99% | +2.97% |
| Perf (abs.) | +1.15 | -4.00 | +2.20 |
| Beta | 0.71 | 0.70 | 0.84 |
| Volatility | 18.15 | 16.99 | 18.19 |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Price data
| Ø price 5 days | Ø volume 5 days (pcs.) | 76.61 CHF (8,677,427) |
| Ø price 30 days | Ø volume 30 days (pcs.) | 78.55 CHF (4,952,098) |
| Ø price 100 days | Ø volume 100 days (pcs.) | 81.80 CHF (4,426,808) |
| Ø price 250 days | Ø volume 250 days (pcs.) | 81.64 CHF (4,219,612) |
| YTD High | date | 86.44 CHF (2023/01/04) |
| YTD Low | date | 73.74 CHF (2023/03/13) |
| 52 Weeks High | date | 88.42 CHF (2022/05/25) |
| 52 Weeks Low | date | 73.32 CHF (2022/09/26) |
All listings for NOVARTIS AG
| Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
| Tradegate | 2019/06/28 | 22:25 | 80.05 EUR | 1.31 | 125 |
| Stuttgart | 2019/06/28 | 21:58 | 80.10 EUR | 0.04 | 11 |
| SIX Swiss Exchange | 2023/03/22 | 17:31 | 76.20 CHF | 412.33 | 12,766 |
| London Stock Exchange European Trade Reporting | 2023/03/22 | 17:20 | 76.96 CHF | 11.97 | 17 |
| Hanover | 2019/06/28 | 08:01 | 80.10 EUR | 0.00 | 2 |
| Hamburg | 2019/06/28 | 14:05 | 80.19 EUR | 0.08 | 4 |
| Frankfurt | 2019/06/28 | 19:57 | 80.16 EUR | 0.13 | 13 |
| FINRA other OTC Issues | 2023/03/21 | 18:03 | 82.74 USD | 0.23 | 11 |
| Duesseldorf | 2019/06/28 | 14:08 | 80.18 EUR | 0.00 | 2 |
| Berlin | 2019/06/28 | 18:45 | 80.40 EUR | 0.00 | 16 |
| BX Swiss | 2023/03/22 | 18:00 | 76.452 CHF | 0.02 | 10 |
Company Logo
Contact Details
| NOVARTIS AG |
| - - |
| Lichtstrasse 35 - 4056 Basel |
| Telefon: +41-61-324-11-11 |
| Fax: +41-61-324-80-01 |
| E-mail: - |
PDF Downloads
| Company report: NOVARTIS AG | |
Company Profile
Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland. |
Members of Management Board
| Vasant Narasimhan, M.D. | Chairman of Managing Board |
| James E. Bradner | Member of Executive Committee |
| Klaus Moosmayer | Member of Executive Committee |
| Steffen Lang | Member of Executive Committee |
| Susanne Schaffert | Member of Executive Committee |
| Harry Kirsch | Member of Executive Committee |
| John Tsai, M.D. | Member of Executive Committee |
| Karen L. Hale | Member of Executive Committee |
| Marie-France Tschudin | Member of Executive Committee |
| Richard Saynor | Member of Executive Committee |
| Rob Kowalski | Member of Executive Committee |
| Robert Weltevreden | Member of Executive Committee |
Board of directors
| Andreas von Planta | Member of the administrative board |
| Charles Sawyers | Member of the administrative board |
| Nancy Andrews | Member of the administrative board |
| Simon Moroney | Member of the administrative board |
| Ana de Pro Gonzalo | Member of the administrative board |
| Bridgette Heller | Member of the administrative board |
| Daniel Hochstrasser | Member of the administrative board |
| Frans van Houten | Member of the administrative board |
| Mary Doherty | Member of the administrative board |
| Patrice Bula | Member of the administrative board |
| Ton Büchner | Member of the administrative board |
| William Winters | Member of the administrative board |
| Hans Jörg Reinhardt | Chairman of the administrative boar |